Skip to content

Study · Animal study (in vivo) · mouse · 2007

12 results

The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice.

Johnston S, Andrews S, Shen V, Cosman F, Lindsay R, Dempster DW, Iida-Klein A

Endocrinology14 Jun 2007Cited by 28 (Europe PMC)

PMID17569757 (opens in a new tab)DOI10.1210/en.2007-0229 (opens in a new tab)PepBankPUB-17569757
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily PTH increased femoral BMD versus vehicle at 7 weeks.

    In plain wordsIn mice, daily PTH increased thigh bone density versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral BMD with daily PTH
    Study

    mousen = 20

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg on 5 days/week · subcutaneous · 7 weeksAs given in this study (mouse).

    Source sentences

    Summary
    At 7 wk, all treatments significantly increased femoral and vertebral bone mineral density.
    3 context sentences
    Summary · context
    3) human PTH(1-34) (40 microg/kg x d) 5 d/wk (daily PTH);
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily PTH increased vertebral BMD versus vehicle at 7 weeks.

    In plain wordsIn mice, daily PTH increased vertebral bone density versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseVertebral BMD with daily PTH
    Study

    mousen = 20

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg on 5 days/week · subcutaneous · 7 weeksAs given in this study (mouse).

    Source sentences

    Summary
    At 7 wk, all treatments significantly increased femoral and vertebral bone mineral density.
    3 context sentences
    Summary · context
    3) human PTH(1-34) (40 microg/kg x d) 5 d/wk (daily PTH);
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, cyclic PTH increased femoral BMD versus vehicle at 7 weeks.

    In plain wordsIn mice, cyclic PTH increased thigh bone density versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral BMD with cyclic PTH
    Study

    mousen = 20

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg on 5 days/week during alternating weeks · subcutaneous · 7 weeksAs given in this study (mouse).

    Source sentences

    Summary
    At 7 wk, all treatments significantly increased femoral and vertebral bone mineral density.
    3 context sentences
    Summary · context
    5) PTH 5 d/wk and vehicle 5 d/wk alternating weekly (cyclic PTH);
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, cyclic PTH increased vertebral BMD versus vehicle at 7 weeks.

    In plain wordsIn mice, cyclic PTH increased vertebral bone density versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseVertebral BMD with cyclic PTH
    Study

    mousen = 20

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg on 5 days/week during alternating weeks · subcutaneous · 7 weeksAs given in this study (mouse).

    Source sentences

    Summary
    At 7 wk, all treatments significantly increased femoral and vertebral bone mineral density.
    3 context sentences
    Summary · context
    5) PTH 5 d/wk and vehicle 5 d/wk alternating weekly (cyclic PTH);
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH increased femoral periosteal circumference.

    In plain wordsIn mice, PTH increased the outer circumference of the thigh bone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePeriosteal circumference
    Study

    mousen: not reported in source

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg on 5 days/week, daily or alternating-week regimens · subcutaneous · 7 weeksAs given in this study (mouse).

    Source sentences

    Summary
    ALN slightly decreased endosteal circumference, whereas PTH increased periosteal circumference, resulting in significant increases in femoral cortical thickness in all groups.
    2 context sentences
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH treatment increased femoral cortical thickness versus control.

    In plain wordsIn mice, PTH increased thigh bone cortical thickness versus control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral cortical thickness
    Study

    mousen: not reported in source

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg on 5 days/week, daily or alternating-week regimens · subcutaneous · 7 weeksAs given in this study (mouse).

    Source sentences

    Summary
    ALN slightly decreased endosteal circumference, whereas PTH increased periosteal circumference, resulting in significant increases in femoral cortical thickness in all groups.
    2 context sentences
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 07AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In mice, PTH and alendronate regimens increased femoral BMD versus vehicle at 7 weeks.

    In plain wordsIn mice, regimens with PTH and alendronate increased thigh bone density versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral BMD with combined regimens
    Study

    mousen: not reported in source

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    At 7 wk, all treatments significantly increased femoral and vertebral bone mineral density.
    2 context sentences
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 08AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In mice, PTH and alendronate regimens increased vertebral BMD versus vehicle at 7 weeks.

    In plain wordsIn mice, regimens with PTH and alendronate increased vertebral bone density versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseVertebral BMD with combined regimens
    Study

    mousen: not reported in source

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    At 7 wk, all treatments significantly increased femoral and vertebral bone mineral density.
    2 context sentences
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 09AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In mice, PTH and alendronate combination regimens increased femoral cortical thickness.

    In plain wordsIn mice, regimens with PTH and alendronate increased thigh bone cortical thickness.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral cortical thickness with combined regimens
    Study

    mousen: not reported in source

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    ALN slightly decreased endosteal circumference, whereas PTH increased periosteal circumference, resulting in significant increases in femoral cortical thickness in all groups.
    2 context sentences
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 10AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In mice, combined PTH and alendronate enhanced lumbar vertebral strength synergistically.

    In plain wordsIn mice, PTH and alendronate together enhanced lumbar vertebral strength synergistically compared with individual treatments.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar vertebral strength with combination
    Study

    mousen: not reported in source

    Twenty-week-old female C57BL/6J mice
    Comparator
    Individual treatments
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    PTH and ALN enhanced bone strength synergistically in the lumbar vertebrae and additively in the femur.
    2 context sentences
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 11AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In mice, combined PTH and alendronate enhanced femoral strength additively.

    In plain wordsIn mice, PTH and alendronate together enhanced thigh bone strength additively compared with individual treatments.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral strength with combination
    Study

    mousen: not reported in source

    Twenty-week-old female C57BL/6J mice
    Comparator
    Individual treatments
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    PTH and ALN enhanced bone strength synergistically in the lumbar vertebrae and additively in the femur.
    2 context sentences
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 12AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In mice, combined PTH and alendronate had no effect on bone markers.

    In plain wordsIn mice, PTH and alendronate together did not change bone markers.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone markers with combination
    Study

    mousen: not reported in source

    Twenty-week-old female C57BL/6J mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Combined therapy, however, had no effects on bone markers.
    2 context sentences
    Summary · context
    Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice.
    Summary · context
    Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.